Genprex Inc reports results for the quarter ended September 30 - Earnings Summary

Genprex

13/11/2024 15:52

* Genprex Inc  GNPX.OQ  reported a quarterly adjusted loss
of
$1.23​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of $-5.20.  The mean expectation of two analysts for the quarter
was for a loss of $1.93 per share. Wall Street expected
results to range from $-2.73 to $-1.13 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Genprex Inc's reported EPS for the quarter was a loss of
$1.23​.
    * The company reported a quarterly loss of $4.32 million.
    * Genprex Inc shares had risen by 477.8% this quarter and
lost 77.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Genprex Inc is
8.75 
This summary was machine generated from LSEG data November 13 at
03:52 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.93          -1.23          Beat
 Jun. 30 2024      -2.30          -3.00          Missed
 Mar. 31 2024      -2.54          -3.69          Missed
 Dec. 31 2023      -3.93          -3.96          Missed